Stage I placental site trophoblastic tumor with complete response after pembrolizumab
•Placental site trophoblastic tumors (PSTT) express PD-L1, making them ideal targets for PD-1 and PD-L1 inhibitors.•For this PSTT patient seeking fertility-sparing treatment, PD-1 inhibition demonstrated complete and sustained response.•Despite anti PD-1 toxicity, there is potential for significant benefit when no alternative fertility-sparing options exists.
Authors
- Pascal Rousset (ORCID: https://orcid.org/0000-0001-6956-2800)
- Jérôme Massardier (ORCID: https://orcid.org/0000-0001-5723-7162)
- Pierre-Adrien Bolze
- François Golfier (ORCID: https://orcid.org/0000-0002-6063-2291)
- Bruno Borghese (ORCID: https://orcid.org/0000-0002-6385-5829)
- Lua Eiriksson
- Touria Hajri (ORCID: https://orcid.org/0000-0003-4226-2298)
- Jérôme Alexandre (ORCID: https://orcid.org/0000-0001-5252-5800)
- Trécourt Alexis
- Benoît You
- Adrien Msika (ORCID: https://orcid.org/0009-0005-7918-0933)
- Pierre Descargues
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Juravinski Cancer Centre (CA)
- Juravinski Hospital (CA)
- Sorbonne Université (FR)
- Hôpital Femme Mère Enfant (FR)
- Centre de Recherche des Cordeliers (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Lyon Sud (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- McMaster University (CA)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1016/j.gore.2026.102023
- Primary Topic
- Gestational Trophoblastic Disease Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00